|Articles|September 11, 2017

CDC Urges Individuals to "Get Ahead of Sepsis"

The CDC has launched an educational initiative called “Get Ahead of Sepsis,” which underscores the early recognition and timely treatment of sepsis.

In light of Sepsis Awareness Month, the Centers for Disease Control and Prevention (CDC) has launched an educational initiative dubbed “Get Ahead of Sepsis.” The initiative underscores the importance of early recognition and timely treatment of sepsis, as well as the importance of preventing infections that could result in sepsis.

The CDC defines sepsis as “the body’s extreme response to an infection.” Therefore, early identification and treatment can be the difference between life and death.

The Get Ahead of Sepsis initiative calls on health care professionals to suspect and identify sepsis early, start treatment quickly, and educate patients on the signs and symptoms associated with sepsis. These symptoms can include any of the following:

  • confusion or disorientation,
  • shortness of breath,
  • high heart rate,
  • fever, or shivering, or feeling very cold,
  • extreme pain or discomfort, and
  • clammy or sweaty skin

In addition, this work urges patients and their families to prevent infections, be alert to the symptoms of sepsis, and seek immediate medical care if sepsis is suspected or for an infection that is not improving or is getting worse.

According to the CDC, about 35% of lung infections, such as pneumonia, lead to sepsis, 25% of kidney or urinary tract infections, 11% of gut, stomach, or intestine infection, and 11% of skin infections result in sepsis. In fact, each year, over 1.5 million individuals get sepsis in the United States, and 250,000 individuals die from it.

“Detecting sepsis early and starting immediate treatment is often the difference between life and death. It starts with preventing the infections that lead to sepsis,” CDC Director Brenda Fitzgerald, MD said in a recent press release. “We created Get Ahead of Sepsis to give people the resources they need to help stop this medical emergency in its tracks.”

The CDC website provides individuals with different resources that can help them “get ahead of sepsis.” These resources include basic information on sepsis, ways to prevent infections, and ways individuals can protect themselves and their families from sepsis.

In 2016, the Surviving Sepsis Campaign published its latest International Guidelines for Management of Sepsis and Septic Shock. The updated guidelines bring slight changes in treatment to encourage the best patient outcomes. The updated guideline states to begin treatment and fluid resuscitation immediately.

The CDC reports that they are going to continue:

  • studying risk factors for sepsis;
  • assisting health care professionals, patients, and families recognize signs of sepsis;
  • developing better ways to measure the impact of successful interventions; and
  • encouraging infection prevention through vaccination programs, chronic disease management, and appropriate antibiotic use.

For more information about Get Ahead of Sepsis, view the video below:

Feature Picture Source: Centers for Disease Control and Prevention


Related to this article

Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
Measles Update: October 23, 2026
The latest CDC numbers show a 4.0% increase in measles cases from week-to-week, bringing the 2026 US total to 4588 confirmed cases. Ninety-six percent of cases are outbreak-associated.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
Measles Update: October 16, 2026
The latest CDC numbers show an 8.1% increase in measles cases from week-to-week, bringing the 2026 US total to 4410 confirmed cases. A CDC disease detective is going to Pennsylvania to aid in the state's massive outbreak, and the agency reports on a rare measles complication that is uniformly fatal.